Literature DB >> 9430409

Acute reserpine administration elicits long-term spontaneous oral dyskinesia.

A N Sussman1, L T Tran-Nguyen, J L Neisewander.   

Abstract

Chronic reserpine administration produces persistent oral dyskinesia accompanied by severe dopamine depletion in the caudate-putamen. The present study examined whether these behavioral and neurochemical effects would persist following acute reserpine administration. Acute administration of reserpine (1 mg/kg, s.c.) produced spontaneous oral dyskinesia that persisted above control levels for at least 84 days. Reserpine also produced a 74% depletion of dopamine in the caudate-putamen relative to vehicle treatment at 3 days post-injection, but did not significantly alter dopamine in the caudate-putamen at 84 days post-injection. The finding that reserpine-induced oral dyskinesia persisted despite repletion of dopamine in the caudate-putamen suggests that the persistent neuropathological change underlying this behavior occurs in a neural pathway other than the dopaminergic nigrostriatal pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430409     DOI: 10.1016/s0014-2999(97)01271-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats.

Authors:  Raquel Cristine Silva Barcelos; Dalila Moter Benvegnú; Nardeli Boufleur; Camila Pase; Angélica Martelli Teixeira; Patrícia Reckziegel; Tatiana Emanuelli; João Batista T da Rocha; Marilise Escobar Bürger
Journal:  Lipids       Date:  2010-12-16       Impact factor: 1.880

3.  Reversal of reserpine-induced orofacial dyskinesia and catalepsy by Nardostachys jatamansi.

Authors:  Rupali A Patil; Yogesh A Hiray; Sanjay B Kasture
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.